Biotech firm Gensight is using gene therapy to treat rare types of blindness.
Founded in 2012, the company is using its technique to treat Leber’s hereditary optic neuropathy (LHON), Labiotech.eu reports. The disease affects people aged 15-25.
It attacks quickly and has a 98 percent probability of complete vision loss within 12 months. About 1,400 to 1,500 people are affected each year in Europe and the United States.
This disease is hereditary, caused changes in mitochondrial DNA.
Read the full story: